FDA Rejects Proposal to Deregulate Certain AI Medical Devices

U.S. Food and Drug Administration (FDA) has rejected a proposal aimed at deregulating certain artificial intelligence (AI) devices in the medical field. According to STAT News, the proposal sought to exempt some low-risk AI tools from premarket review requirements.

The FDA's decision preserves the existing regulatory framework for these devices. This rejection comes amid ongoing discussions about balancing innovation with patient safety in health technology. AI devices, which include software for diagnostics and treatment recommendations, have proliferated in recent years.

The FDA has approved over 500 such devices since 2012, but concerns about efficacy and risks persist.

A pharmaceutical company has invested $50 million in digital therapeutics (DTx), which are evidence-based software interventions for managing health conditions.

STAT News reported this funding as part of broader industry efforts to advance non-drug treatments. Digital therapeutics target areas such as mental health, chronic disease management, and behavioral change. The investment highlights growing interest in integrating technology with traditional healthcare.

Stakeholders include patients who may access these tools via apps or platforms, as well as providers seeking scalable solutions. Regulatory bodies like the FDA continue to evaluate DTx for safety and effectiveness, with several products already authorized.

The FDA's stance on AI regulation affects developers, healthcare providers, and patients relying on these technologies.

Companies must now adhere to standard clearance pathways, such as the 510(k) process, which can extend timelines and costs. Future proposals may revisit deregulation if new data emerges on low-risk applications. In the digital therapeutics space, the $50 million infusion could accelerate research and clinical trials.